Key Points
- Director Gregory Lucier sold 82,200 shares of DENTSPLY SIRONA on Dec. 8 at an average price of $11.14, totaling $915,708, per an SEC filing.
- The company missed quarterly EPS ($0.37 vs. $0.45 estimate), reported $904M in revenue (down 4.9% YoY) and set FY2025 guidance at 1.60 EPS while showing a negative net margin of -24.34%.
- Analysts are largely cautious—the stock has a consensus rating of "Reduce" with an average price target of $15.77 after several recent price-target cuts.
DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Get Free Report) Director Gregory Lucier sold 82,200 shares of DENTSPLY SIRONA stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $11.14, for a total value of $915,708.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
DENTSPLY SIRONA Stock Up 4.9%
Shares of NASDAQ:XRAY opened at $11.65 on Thursday. The company has a quick ratio of 0.99, a current ratio of 1.47 and a debt-to-equity ratio of 1.36. The firm has a market cap of $2.32 billion, a P/E ratio of -2.64, a P/E/G ratio of 0.81 and a beta of 1.01. DENTSPLY SIRONA Inc. has a 12 month low of $9.85 and a 12 month high of $20.59. The company's 50-day moving average price is $11.81 and its two-hundred day moving average price is $13.82.
DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $0.37 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.45 by ($0.08). The company had revenue of $904.00 million for the quarter, compared to analyst estimates of $900.33 million. DENTSPLY SIRONA had a positive return on equity of 17.10% and a negative net margin of 24.34%.DENTSPLY SIRONA's revenue for the quarter was down 4.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.50 earnings per share. DENTSPLY SIRONA has set its FY 2025 guidance at 1.600-1.600 EPS. As a group, research analysts forecast that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current fiscal year.
Hedge Funds Weigh In On DENTSPLY SIRONA
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in XRAY. Brooklyn Investment Group bought a new stake in shares of DENTSPLY SIRONA in the 1st quarter valued at about $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in DENTSPLY SIRONA during the 1st quarter worth $26,000. Trust Co. of Toledo NA OH bought a new position in DENTSPLY SIRONA during the second quarter worth about $27,000. Parkside Financial Bank & Trust increased its holdings in shares of DENTSPLY SIRONA by 620.6% in the second quarter. Parkside Financial Bank & Trust now owns 1,715 shares of the medical instruments supplier's stock worth $27,000 after acquiring an additional 1,477 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in shares of DENTSPLY SIRONA by 8,003.6% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,269 shares of the medical instruments supplier's stock valued at $34,000 after purchasing an additional 2,241 shares in the last quarter. Institutional investors own 95.70% of the company's stock.
Analyst Ratings Changes
Several equities research analysts have recently commented on XRAY shares. UBS Group lowered their target price on DENTSPLY SIRONA from $24.00 to $23.00 and set a "buy" rating for the company in a research note on Tuesday, October 28th. JPMorgan Chase & Co. decreased their price target on DENTSPLY SIRONA from $14.00 to $12.00 and set a "neutral" rating on the stock in a report on Friday, November 7th. Wells Fargo & Company dropped their price objective on DENTSPLY SIRONA from $15.00 to $12.00 and set an "equal weight" rating for the company in a report on Friday, November 7th. Wall Street Zen downgraded shares of DENTSPLY SIRONA from a "buy" rating to a "hold" rating in a research report on Saturday, October 18th. Finally, Barrington Research lowered their price target on shares of DENTSPLY SIRONA from $18.00 to $14.00 and set an "outperform" rating for the company in a research report on Monday, November 10th. Two analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Reduce" and a consensus price target of $15.77.
Check Out Our Latest Stock Analysis on DENTSPLY SIRONA
About DENTSPLY SIRONA
(
Get Free Report)
DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
